Unknown PHASE1 INTERVENTIONAL 1-arm NCT02287064

An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias

Sponsor: Baxter Healthcare Corporation

Interventions Intravenous Immune Globulin (IVIG)

Updated 7 times since 2017 Last updated: Jun 6, 2016 Started: Apr 30, 2015 Primary completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02287064, this PHASE1 trial focuses on Spinocerebellar Ataxias and remains ongoing. Sponsored by Baxter Healthcare Corporation, it has been updated 7 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jul 2018 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baxter Healthcare Corporation
University of South Florida

Data source: University of South Florida

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tampa, United States